Last reviewed · How we verify

Lorelco — Competitive Intelligence Brief

Lorelco (PROBUCOL) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: probucol. Area: Metabolic.

marketed probucol Serine protease hepsin Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Lorelco (PROBUCOL).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lorelco TARGET PROBUCOL marketed probucol Serine protease hepsin 1977-01-01
Antivert meclizine Generic (originally Pfizer/UCB) marketed Antihistamine/Antiemetic (vestibular suppressant) Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor 1957-01-01
Anthralin dithranol marketed dithranol Arachidonate 12-lipoxygenase, 12R-type, NAD-dependent protein deacylase sirtuin-5, mitochondrial, Serine protease hepsin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (probucol class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lorelco — Competitive Intelligence Brief. https://druglandscape.com/ci/probucol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: